Bio Plus Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Hyun-Kyu Jung
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 31.3% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
No updates
Recent updates
Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up
Jan 07
Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return
Dec 15Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit
Nov 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%
Jul 23The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence
Jul 05More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%
Jun 08Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings
Mar 26CEO
Hyun-Kyu Jung
no data
Tenure
Hyun-Kyu Jung serves as Chief Executive Officer of Bio Plus Co., Ltd.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:23 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |
| Junghyun Kim | Kyobo Securities Co., Ltd |
| Jaehee Won | Shinhan Investment Corp. |